Immunome (IMNM) director Carol Schafer receives grant of 9,897 stock options

Rhea-AI Filing Summary

Immunome Inc. director Carol Schafer received a grant of stock options as part of her compensation. She was awarded options covering 9,897 shares of common stock at an exercise price of $18.16 per share, expiring on June 9, 2036.

The options vest in four equal quarterly installments starting on June 10, 2026, continuing on the same day of each succeeding fiscal quarter for one year, as long as she remains in continuous service with the company. Following this grant, she directly holds options for 9,897 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SCHAFER CAROL

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	9,897	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 9,897 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 9,897 options Exercise price: $18.16 per share Expiration date: June 9, 2036 +2 more

5 metrics

Options granted 9,897 options Director stock option grant to Carol Schafer

Exercise price $18.16 per share Director stock option strike price

Expiration date June 9, 2036 Option term end date

Underlying shares 9,897 shares Common stock underlying granted options

Post-grant derivative holdings 9,897 options Total options held following transaction

Key Terms

Director Stock Option, exercise price, vesting, continuous service, +1 more

5 terms

Director Stock Option financial

"security_title: "Director Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "18.1600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests in four equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to the Reporting Person's continuous service with the Company"

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHAFER CAROL

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$18.16	06/10/2026		A		9,897		(1)	06/09/2036	Common Stock	9,897	$0	9,897	D

Explanation of Responses:

1. The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

	/s/ Sandra Stoneman, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Immunome (IMNM) director Carol Schafer report on this Form 4?

Carol Schafer reported receiving a grant of 9,897 director stock options in Immunome. These options give her the right to buy an equal number of common shares at a fixed exercise price as part of her director compensation package.

How many Immunome (IMNM) stock options were granted to Carol Schafer?

She was granted stock options for 9,897 shares of Immunome common stock. All 9,897 options are shown as held directly after the transaction, representing a new equity-based compensation award rather than an open-market purchase or sale.

What is the exercise price and expiration date of Carol Schafer’s Immunome options?

The options have an exercise price of $18.16 per share and expire on June 9, 2036. This means she can buy Immunome common stock at $18.16 any time before expiration, once each portion of the grant has vested.

How do the Immunome (IMNM) director stock options granted to Carol Schafer vest?

The option vests in four equal quarterly installments beginning on June 10, 2026. Each additional quarter over the following year another portion vests, provided she remains in continuous service with Immunome on each vesting date.

Does this Immunome (IMNM) Form 4 show any open-market buying or selling?

No, the filing reflects a grant of director stock options coded as an acquisition (A). It is a compensation-related award, not an open-market purchase or sale of existing Immunome common shares by the director.